Shots:

• The MAA submission to ANVISA is based on P-III APOLLO study results assessing Onpattro in patients hATTR amyloidosis with polyneuropathy- evaluating its safety and efficacy and the results are also published in The New England Journal of Medicine in July 5- 2018
• Alnylam’s Onpattro has also received ANIVSA’s Priority Review which is granted to innovative medicines treating rare diseases under this accelerated regulatory pathway with its expected decision in H1’20
• Onpattro is an RNAi therapeutic that targets and silence TTR messenger RNA- further blocking the production of TTR protein before it is made targeting transthyretin (TTR)- approved in Canada- Japan and the US FDA for polyneuropathy of hATTR amyloidosis in adults and in EU and Switzerland for hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy

Click here to­ read full press release/ article | Ref: PRNewsWire | Image: Twitter